Introduction: Several attempts to determine prognostic factors in neuroendocrine setting have been made, with inconsistent results until now. Alpha-fetoprotein (AFP) has previously been reported as being elevated in some neuroendocrine neoplasms (NENs), even if the actual clinical implications of this marker in this setting are unclear.
Aim(s): Our prospective series was aimed at evaluating the role of AFP as tumor marker in monitoring patients with gastro-entero-pancreatic (GEP)-NENs.
Materials and methods: Between January 2000 and September 2017, all patients with GEP-NENs, were consecutively enrolled and followed-up at our Unit. All the patients were tested for AFP, tumor antigens (CA 125, Ca19.9, CEA, CA 15.3, NSE), Chromogranin A (CgA). Pertinent clinical and histologic data were recorded.
Conference: 15th Annual ENETS conference (2018)
Presenting Author: MD Roberta Elisa Rossi
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: MD, PhD Sara Massironi
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Sara Massironi
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Presenting Author: Dr Roberta E Rossi
Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.
Presenting Author: Dr Roberta Elisa Rossi
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dr Sara Massironi